Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 11, 2003

View Archived Issues

NeoPharm to resume LEP clinical trials

Antitumor protein tyrosine kinase inhibitors newly identified at Pfizer

New analgesic agents in early development at Gruenenthal

Merck researchers describe new DPP-IV inhibitors for diabetes and other disorders

Antiarrhythmic benzopyran derivatives prepared and tested at Nissan Chemical

NPS updates clinical progress

Atheroprotective effects of statins

FK-960 distribution evaluated in rhesus monkeys

Revotar and Texas Biotechnology amend bimosiamose license agreement

BioCryst refocuses resources following termination of peramivir agreement

Rigel reports accomplishments in 2002 and outlook for 2003

Pilot study for DB-289 completes enrollment

Phase II/III trial planned for iseganan for prevention of VAP

Metvix launched in Germany

FDA approves Avonex for early MS

Merck & Co. discontinues development of GABA agonist

MIV-210 enters phase I study of multiple oral doses

Fludara receives E.U. approval as first-line treatment for B-CLL

Wyeth presents various series of PAI-1 inhibitors

New ORL1 modulators in early development at Pfizer

Raptiva enters phase II trial in psoriatic arthritis

Novo Nordisk updates progress of R&D portfolio

First potent human MC1 receptor antagonist disclosed in recent article

Clinical toxicity and pharmacokinetics determined for lead alkycycline

Beneficial effects for SAR-943 on inflammation and remodeling in murine asthma model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...